Clinical trial
Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT02420795 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 3, 2015
- Completion date
- November 16, 2020
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
central nervous system lymphoma, gastric mantle cell lymphoma, recurrent mantle cell lymphoma, recurrent non-hodgkin lymphoma, refractory mantle cell lymphoma, refractory non-hodgkin lymphoma, splenic mantle cell lymphoma